EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice

Ye-Eul Lee, Dong-Soon Im iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25147567 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Ye-Eul Lee und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Fundamental Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02446, Republic of Korea. Hauptthemen laut MEDLINE: Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Asthma, Glucosides. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Basic Science Research Program of the Korean National Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Inhibitors of sodium/glucose cotransporter 2 (SGLT2), such as empagliflozin and canagliflozin, have been widely used to block glucose reabsorption in the proximal tubules of kidneys in patients with diabetes. A meta-analysis suggested that SGLT2 inhibitors are associated with a decreased risk of asthma development. Therefore, we investigated whether SGLT2 inhibitors could suppress allergic asthma. Empagliflozin and canagliflozin suppressed the in vitro degranulation reaction induced by antigens in a concentration-dependent manner in RBL-2H3 mast cells. Empagliflozin and canagliflozin were administered to BALB/c mice sensitized to ovalbumin (OVA). The administration of empagliflozin or canagliflozin significantly suppressed OVA-induced airway hyper-responsiveness and increased the number of immune cells and pro-inflammatory cytokine mRNA expression levels in bronchoalveolar lavage fluid. The administration of empagliflozin and canagliflozin also suppressed OVA-induced histopathological changes in the lungs. Empagliflozin and canagliflozin also suppressed serum IgE levels. These results suggested that empagliflozin and canagliflozin may be applicable for the treatment of allergic asthma by suppressing immune responses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CanagliflozinSodium-Glucose Transporter 2 InhibitorsAsthmaGlucosidesBenzhydryl CompoundsMice, Inbred BALB COvalbuminAnimalsMiceLungMast CellsImmunoglobulin EBronchoalveolar Lavage FluidRatsCytokinesCell DegranulationDisease Models, AnimalSodium-Glucose Transporter 2Male

Stichwörter der Autor:innen

SGLT2allergyasthmacanagliflozinpulmonary pharmacology

Substanzen

empagliflozinCanagliflozinSodium-Glucose Transporter 2 InhibitorsGlucosidesBenzhydryl CompoundsOvalbuminImmunoglobulin ECytokinesSodium-Glucose Transporter 2

Autor:innen und Institutionen

  • Department of Fundamental Pharmaceutical Sciences, Graduate School, Kyung Hee University, Seoul 02446, Republic of Korea.

ORCID-Profile: Dong-Soon Im

Förderung

  • National Research Foundation of Korea
  • Basic Science Research Program of the Korean National Research Foundation

Zitieren

APA

Lee, Y. E., & Im, D. S. (2024). SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25147567

Vancouver

Lee YE, Im DS. SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25147567

BibTeX
@article{Lee2024,
  author = {Lee, Ye-Eul and Im, Dong-Soon},
  title = {SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25147567}
}
Kostenlos starten →